title: Accuracy of the stool antigen test in the diagnosis of Helicobacter pylori infection before treatment and in patients on omeprazole therapy.
abstract: OBJECTIVE
  To evaluate the Helicobacter pylori stool antigen (HpSA) test in the assessment of H. pylori infection and the effect of omeprazole treatment on its accuracy.
  
  
  METHODS
  Study 1: 140 dyspeptic patients were enrolled in the study and defined as H. pylori positive if histology and rapid urease test, or culture alone were positive. HpSA was performed on all patients and 13C-urea breath test (UBT) on 87. Study 2: 75 patients testing positive using both UBT and HpSA, were given omeprazole 20 mg for 2 weeks (Group A) or omeprazole 40 mg for 2 weeks (Group B), or OAC for 1 week (group C). A Helicobacter pylori stool antigen test was performed on all patients on days 3, 5, 7 and 14 during treatment, and also on days 7 and 14 post-treatment in groups A and B. UBT was performed in groups A and B on days 7 and 14 during treatment, and days 7 and 14 post-treatment.
  
  
  RESULTS
  80/140 patients were H. pylori positive. The sensitivity and specificity of HpSA were 93.8 and 90%, similar to UBT (93.9 and 92.1%). Omeprazole significantly reduced both HpSA and UBT values, resulting in a decreased accuracy. Of 25 patients receiving 20 mg omeprazole, HpSA gave 5 and 6 false negatives after 7 and 14 days treatment respectively, while UBT gave 4 and 7 false negatives after 7 and 14 days treatment. Of 25 patients receiving 40 mg omeprazole, HpSA gave 7 and 9 false negatives after 7 and 14 days of treatment, while UBT gave 8 and 9 false negatives after 7 and 14 days of treatment. Two weeks after stopping omeprazole treatment, the HpSA and UBT were positive in all cases.
  
  
  CONCLUSIONS
  The Helicobacter pylori stool antigen test is valuable in the assessment of H. pylori infection. Short-term omeprazole treatment decreases the accuracy of both HpSA and UBT in a similar manner.
authors.affiliation: Department of Gastroenterology, Cardarelli Hospital, Napoli, Italy. gimanes@tin.it
authors.forename: G
authors.initials: G
authors.lastname: Manes
authors.forename: A
authors.initials: A
authors.lastname: Balzano
authors.forename: G
authors.initials: G
authors.lastname: Iaquinto
authors.forename: C
authors.initials: C
authors.lastname: Ricci
authors.forename: M M
authors.initials: MM
authors.lastname: Piccirillo
authors.forename: N
authors.initials: N
authors.lastname: Giardullo
authors.forename: A
authors.initials: A
authors.lastname: Todisco
authors.forename: M
authors.initials: M
authors.lastname: Lioniello
authors.forename: D
authors.initials: D
authors.lastname: Vaira
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000942:Antigens, Bacterial / Q000032:analysis*; D001944:Breath Tests; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005243:Feces / Q000382:microbiology*; D005260:Female; D016481:Helicobacter Infections / Q000175:diagnosis* / Q000188:drug therapy; D016480:Helicobacter pylori / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use*
chemical_list: D000942:Antigens, Bacterial; D004791:Enzyme Inhibitors; D009853:Omeprazole